; Nymox Pharmaceutical Corporation (NYMX) - Financial and Strategic SWOT Analysis Review
Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out
Your Federal Quarterly Tax Payments are due April 15th Get Help Now >>

Nymox Pharmaceutical Corporation (NYMX) - Financial and Strategic SWOT Analysis Review

VIEWS: 24 PAGES: 35

Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company. It undertakes the research and development of therapeutics and diagnostics devices to target the unmet needs of the aging population. The company’s marketed products include, NX-1207, administered by a urologist and is used for the treatment of BPH (benign prostatic hyperplasia). The company has a pipeline of therapeutic drugs in development for the treatment of diseases such as Alzheimer’s disease (AD), enlarged prostate (benign prostatic hyperplasia or BPH), and anti bacterial agents for treating the bacterial infections in humans which include E. coli O157:H7 contamination of food and drink products. It focuses on protein markers, subcellular pathology, cell death, cell proliferation, clinical models, genetic expression, morphology, and drug screening design, assays, and development. Nymox is headquartered in Quebec, Canada.

More Info
  • pg 1
									           Nymox Pharmaceutical Corporation (NYMX) - Financial and Strategic
                              SWOT Analysis Review
        Reference Code: GDPH63111FSA                                                                                          Publication Date: SEP 2012

          9900 Cavendish Boulevard, Suite 306                Phone              NA                              Revenue          3.1 (million USD)
          St. Laurent, QC                                    Fax                +1 514 3322227                  Net Profit       -9.65 (million USD)
          H4M 2V2                                            Website            www.nymox.com                   Employees        26
                                                                                                                                 Pharmaceuticals           &
          Canada                                             Exchange           NYMX [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Nymox Pharmaceutical Corporation (Nymox) is a biopharmaceutical company. It undertakes the research and development of
       therapeutics and diagnostics devices to target the unmet needs of the aging population. The company’s marketed products
       include, NX-1207, administered by a urologist and is used for the treatment of BPH (benign prostatic hyperplasia). The company
       has a pipeline of therapeutic drugs in development for the treatment of diseases such as Alzheimer’s disease (AD), enlarged
       prostate (benign prostatic hyperplasia or BPH), and anti bacterial agents for treating the bacterial infections in humans which
       include E. coli O157:H7 contamination of food and drink products.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Nymox Pharmaceutical Corporation, SWOT Analysis
         Paul Averback, M.D.                 Chairman                                 Strengths                              Weaknesses
         Jack Gemmell                        Chief Information Officer
                                                                                      Patent Portfolio                       Dependence on Contract
         Randall Lanham                      Director                                                                        Manufacturers
                                                                                      Strong In-house Research
         Paul F. McDonald                    Director
                                                                                      Capabilities                           History of Losses
         David Morse, Ph.D.                  Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Market Potential: Alzheimer's          Competitive Pressures
         Nymox Pharmaceutical Corporation                                             disease
                                                                                                                             Government Regulation
        Share Price (USD) as on 04-Sep-                                  6.21         Emerging Markets
        2012
        EPS (USD)                                                       -0.30
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                         206         GlobalData

        Enterprise Value (million USD)                                   204
        Shares Outstanding (million)                                       33
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Aug 14, 2012         Nymox Pharma Reports Q2 2012 Results
                                                                                      May 15, 2012         Nymox Pharma Reports Q1 2012 Results
                                                                                      Mar 15, 2012         Nymox Pharmaceutical Reports 2011 Results
                                                                                      Nov 14, 2011         Nymox Pharmaceutical Reports Q3 2011
                                                                                                           Results
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData




       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Nymox Pharmaceutical Corporation (NYMX) - Financial and                                                                        Reference Code: GDPH63111FSA
Strategic SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Nymox Pharmaceutical Corporation - Key Facts ................................................................................................................................ 5
       Nymox Pharmaceutical Corporation - Key Employees ....................................................................................................................... 6
       Nymox Pharmaceutical Corporation - Key Employee Biographies ..................................................................................................... 7
       Nymox Pharmaceutical Corporation - Major Products and Services .................................................................................................. 8
       Nymox Pharmaceutical Corporation - Pharmaceutical Pipeline Products Data .................................................................................. 9
          Nymox Pharmaceutical Corporation, Pipeline Products by Therapy Area ...................................................................................... 9
          Nymox Pharmaceutical Corporation, Pipeline Products by Development Phase.......................................................................... 10
       Nymox Pharmaceutical Corporation - History................................................................................................................................... 12
       Nymox Pharmaceutical Corporation - Company Statement ............................................................................................................. 14
       Nymox Pharmaceutical Corporation - Locations And Subsidiaries................................................................................................... 15
          Head Office ................................................................................................................................................................................... 15
          Other Locations & Subsidiaries ..................................................................................................................................................... 15
       Section 2 – Company Analysis ......................................................................................................................................................... 16
       Nymox Pharmaceutical Corporation - Business Description ............................................................................................................ 16
       Nymox Pharmaceutical Corporation - SWOT Analysis ..................................................................................................................... 17
          SWOT Analysis - Overview........................................................................................................................................................... 17
          Nymox Pharmaceutical Corporation - Strengths ........................................................................................................................... 17
             Strength - Patent Portfolio ......................................................................................................................................................... 17
             Strength - Strong In-house Research Capabilities .................................................................................................................... 17
          Nymox Pharmaceutical Corporation - Weaknesses ...................................................................................................................... 17
             Weakness - Dependence on Contract Manufacturers ............................................................................................................... 17
             Weakness - History of Losses ................................................................................................................................................... 17
          Nymox Pharmaceutical Corporation - Opportunities ..................................................................................................................... 18
             Opportunity - Market Potential: Alzheimer's disease ................................................................................................................. 18
             Opportunity - Emerging Markets ............................................................................................................................................... 18
          Nymox Pharmaceutical Corporation - Threats .............................................................................................................................. 18
             Threat - Competitive Pressures ................................................................................................................................................. 18
             Threat - Government Regulation ............................................................................................................................................... 18
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 18
       Nymox Pharmaceutical Corporation - Key Competitors ................................................................................................................... 20
       Section 3 – Company Financial Ratios ............................................................................................................................................. 21
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 21
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 21
       Performance Chart ........................................................................................................................................................................... 23
       Financial Performance...................................................................................................................................................................... 23
       Financial Ratios - Interim Ratios....................................................................................................................................................... 24
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 25
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 26
          Nymox Pharmaceutical Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 ................................... 26
          Nymox Pharmaceutical Corporation, Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 ................................... 27
       Nymox Pharmaceutical Corporation, Recent Deals Summary ......................................................................................................... 28


Nymox Pharmaceutical Corporation (NYMX) - Financial and                                                                                                        Reference Code: GDPH63111FSA
Strategic SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Section 5 – Company’s Recent Developments ................................................................................................................................ 29
          Nymox Pharmaceutical Corporation, Recent Developments ........................................................................................................ 29
             Aug 14, 2012: Nymox Pharma Reports Q2 2012 Results .....................................
								
To top